Wire · opportunities
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 11 September 2026 · Fusion42 review
The U.S. FDA has approved Pharming's Joenja® as the first treatment for children with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS), marking a significant regulatory milestone in paediatric immunodeficiency therapies.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now face a new market opportunity as an FDA-approved therapy creates demand for specialised paediatric immunodeficiency treatments, opening access paths for drug makers who target rare genetic conditions.
◆ Coverage
1 source · 11 Sep 2026
◆ Related on Wire
◆ Topics
Biotechfda-approvalpaediatric-immunotherapyrare-diseasespharmingjoenja